JHVEPhoto/iStock Editorial via Getty Images Edwards Lifesciences ( NYSE: EW ) announced Wednesday that its pivotal TRISCEND II trial for its Evoque tricuspid valve replacement (TTVR) system reached its one-year primary endpoint in patients with tricuspid regurgitation (TR), a heat value disease. Evoque, the world's first and only approved.
Back to Health Page
